Related Experiment Video
Updated: May 2, 2026

Vibrio cholerae: Model Organism to Study Bacterial Pathogenesis - Interview
Published on: May 28, 2007
High-throughput screening and whole genome sequencing identifies an antimicrobially active inhibitor of Vibrio
Galina Sergeev, Sambit Roy, Michael Jarek
1Department of Chemical Biology, Helmholtz Centre for Infection Research (HZI), Inhoffenstraße 7, D-38124 Braunschweig, Germany. nandy_rk@hotmail.com.
Background:
Pathogenic serotypes of Vibrio cholerae cause the life-threatening diarrheal disease cholera. The increasing development of bacterial resistances against the known antibiotics necessitates the search for new antimicrobial compounds and targets for this pathogen.
Results:
A high-throughput screening assay with a Vibrio cholerae reporter strain constitutively expressing green fluorescent protein (GFP) was developed and applied in the investigation of the growth inhibitory effect of approximately 28,300 structurally diverse natural compounds and synthetic small molecules. Several compounds with activities in the low micromolar concentration range were identified. The most active structure, designated vz0825, displayed a minimal inhibitory concentration (MIC) of 1.6 μM and a minimal bactericidal concentration (MBC) of 3.2 μM against several strains of V. cholerae and was specific for this pathogen. Mutants with reduced sensitivity against vz0825 were generated and whole genome sequencing of 15 pooled mutants was carried out. Comparison with the genome of the wild type strain identified the gene VC_A0531 (GenBank: AE003853.1) as the major site of single nucleotide polymorphisms in the resistant mutants. VC_A0531 is located on the small chromosome of V. cholerae and encodes the osmosensitive K+-channel sensor histidine kinase (KdpD). Nucleotide exchange of the major mutation site in the wild type strain confirmed the sensitive phenotype.
Conclusion:
The reporter strain MO10 pG13 was successfully used for the identification of new antibacterial compounds against V. cholerae. Generation of resistant mutants and whole genome sequencing was carried out to identify the histidine kinase KdpD as a novel antimicrobial target.
Insights
Researchers identified a new compound, vz0825, that inhibits Vibrio cholerae growth. By studying resistant mutants, they discovered the KdpD histidine kinase as a novel antimicrobial target for cholera treatment.
Area of Science:
- Microbiology
- Drug Discovery
- Genomics
Background:
- Pathogenic Vibrio cholerae causes cholera, a severe diarrheal disease.
- Rising antibiotic resistance in V. cholerae necessitates novel therapeutic strategies and drug targets.
Purpose of the Study:
- To identify new antimicrobial compounds effective against Vibrio cholerae.
- To discover novel molecular targets for antibacterial drug development against V. cholerae.
Main Methods:
- Development of a high-throughput screening assay using a Vibrio cholerae reporter strain expressing green fluorescent protein (GFP).
- Screening of approximately 28,300 natural compounds and synthetic small molecules for growth inhibitory effects.
- Generation of resistant mutants, whole genome sequencing, and identification of target genes through comparative genomics.
Main Results:
- Identification of several compounds with low micromolar activity, including vz0825 (MIC 1.6 μM, MBC 3.2 μM), specific to V. cholerae.
- Whole genome sequencing of resistant mutants pinpointed the osmosensitive K+-channel sensor histidine kinase (KdpD) encoded by VC_A0531 as the primary target.
- Confirmation of KdpD's role through nucleotide exchange experiments in the wild type strain.
Conclusions:
- A novel reporter strain (MO10 pG13) effectively facilitated the discovery of new antibacterial agents against V. cholerae.
- The histidine kinase KdpD is validated as a promising novel antimicrobial target for combating V. cholerae infections.
More Related Videos
Related Concept Videos
Cholera
Automated Microbial Diagnostics

